Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AK112 + etoposide + carboplatin
- Development stage
- Unknown
- Lead developer
- Akeso
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
AK112 + etoposide + carboplatin is a combination therapy consisting of ivonescimab (AK112), etoposide, and carboplatin, being investigated primarily for the treatment of advanced non-small cell lung cancer (NSCLC). AK112 (ivonescimab) is a first-in-class bispecific IgG1 monoclonal antibody that simultaneously targets programmed death-1 (PD-1) and vascular endothelial growth factor (VEGF), providing both checkpoint inhibition (immunotherapy) and anti-angiogenic effects. Etoposide and carboplatin are established cytotoxic chemotherapy agents: etoposide inhibits topoisomerase II, causing DNA strand breaks, while carboplatin is a platinum-based agent that forms DNA crosslinks, inhibiting DNA synthesis. The combination aims to enhance antitumor effects by leveraging immunomodulation alongside direct cytotoxicity. The regimen is administered intravenously and is being evaluated in multiple clinical settings, especially in advanced NSCLC both in untreated and pretreated populations[1][5][7].
- Brand names
- Ivonescimab
- Other names
- SMT112SMT-112SMT 112
02
Targets
TOP2A (DNA topoisomerase II)PDCD1 (Programmed cell death protein 1 receptor)VEGFA (Vascular endothelial growth factor A)DNA
Beyond the preview
Go deeper on AK112 + etoposide + carboplatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AK112 + etoposide + carboplatin.